Poolbeg Pharma commences trading on OTCQB Market in the United States
Poolbeg Pharma PLC (POLB.L) Confirmation of vaccine platform licence execution
31 January 2022 – Poolbeg Pharma (AIM: POLB, ‘Poolbeg’ or the ‘Company’) a clinical-stage infectious disease pharmaceutical company with a capital-light clinical model, confirms that it has signed the licence
Poolbeg Pharma (LSE:POLB) Year in (Video) Review 2021
Targeting the growing infectious disease market, we are developing multiple assets quickly to Phase II ready with plans to monetise early to Big Pharma. POLB spun out of Open Orphan
Share Talk catches up with CEO Jeremy Skillington, Poolbeg Pharma (LON: POLB) Interview
Share Talk caught up with our CEO to discuss yesterday’s announcement on #POLB’s has signed a binding term sheet, encompassing all commercial terms, with AnaBio Technologies (AnaBio), with a full
Poolbeg Pharma (POLB.L) agrees terms to develop an oral vaccine delivery platform
16 December, 2021- Poolbeg Pharma (AIM: POLB, ‘Poolbeg’ or the ‘Company’) a clinical stage infectious disease pharmaceutical company with a capital light clinical model, has signed a binding term sheet,